Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit?
Chapiro J, Duran R, Geschwind JF. Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit? La Radiologia Medica 2014, 119: 476-482. PMID: 24894921, DOI: 10.1007/s11547-014-0413-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBiomarkers, TumorCarcinoma, HepatocellularChemoembolization, TherapeuticEmbolization, TherapeuticHepatectomyHepatic ArteryHumansInfusions, Intra-ArterialLiver NeoplasmsMicrospheresNeoplasm StagingNiacinamidePhenylurea CompoundsRadiography, InterventionalSorafenibSurvival RateConceptsIntra-arterial therapySurvival benefitIntroduction of sorafenibLoco-regional approachesAdvanced stage diseaseSignificant survival benefitUnresectable hepatocellular carcinomaLocal tumor controlTreatment of patientsSequence of administrationConventional systemic chemotherapyInternational clinical trialsOral monotherapySystemic chemotherapyExciting new optionsClinical outcomesTransarterial chemoembolizationClinical benefitSafety profileTumor controlClinical trialsHepatocellular carcinomaNovel agentsPotential biomarkersSystemic toxicity